Envestnet Asset Management Inc. Lowers Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Envestnet Asset Management Inc. cut its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 31.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 984,678 shares of the company's stock after selling 460,843 shares during the quarter. Envestnet Asset Management Inc.'s holdings in Takeda Pharmaceutical were worth $13,037,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in TAK. Blair William & Co. IL increased its holdings in Takeda Pharmaceutical by 8.1% during the fourth quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock worth $162,000 after buying an additional 913 shares during the last quarter. Sage Rhino Capital LLC increased its stake in shares of Takeda Pharmaceutical by 14.9% during the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock worth $157,000 after purchasing an additional 1,538 shares during the last quarter. Aaron Wealth Advisors LLC raised its holdings in shares of Takeda Pharmaceutical by 7.2% in the 4th quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company's stock worth $331,000 after purchasing an additional 1,670 shares during the period. OLD Mission Capital LLC lifted its stake in Takeda Pharmaceutical by 13.7% in the fourth quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock valued at $185,000 after purchasing an additional 1,687 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Takeda Pharmaceutical by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock valued at $69,000 after purchasing an additional 1,770 shares during the period. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Stock Performance

NYSE TAK traded up $0.40 during trading on Tuesday, hitting $15.33. 1,923,867 shares of the company's stock traded hands, compared to its average volume of 1,856,582. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The stock has a market capitalization of $48.76 billion, a price-to-earnings ratio of 38.31, a PEG ratio of 0.24 and a beta of 0.39. Takeda Pharmaceutical Company Limited has a 12-month low of $12.58 and a 12-month high of $15.37. The business has a 50 day moving average of $14.64 and a 200-day moving average of $13.92.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.